1
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A Review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kunisaki C, Makino H, Kimura J, Oshima T,
Fujii S, Takagawa R, Kosaka T, Ono HA and Akiyama H: Impact of
lymph-node metastasis site in patients with thoracic esophageal
cancer. J Surg Oncol. 101:36–42. 2010. View Article : Google Scholar
|
3
|
Rice TW, Rusch VW, Apperson-Hansen C,
Allen MS, Chen LQ, Hunter JG, Kesler KA, Law S, Lerut TE, Reed CE,
et al: Worldwide esophageal cancer collaboration. Dis Esophagus.
22:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Mizoguchi K, Ishiguro H, Kimura M,
Takahashi H, Sakamoto N, Tanaka T and Takeyama H: Induction of
apoptosis by eicosapentaenoic acid in esophageal squamous cell
carcinoma. Anticancer Res. 34:7145–7149. 2014.PubMed/NCBI
|
5
|
Zhu X, Ding M, Yu ML, Feng MX, Tan LJ and
Zhao FK: Identification of galectin-7 as a potential biomarker for
esophageal squamous cell carcinoma by proteomic analysis. BMC
Cancer. 10:2902010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Shigeoka M, Urakawa N, Nishio M, Takase N,
Utsunomiya S, Akiyama H, Kakeji Y, Komori T, Koma Y and Yokozaki H:
Cyr61 promotes CD204 expression and the migration of macrophages
via MEK/ERK pathway in esophageal squamous cell carcinoma. Cancer
Med. 4:437–446. 2015. View
Article : Google Scholar : PubMed/NCBI
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Schaefer JS, Attumi T, Opekun AR, Abraham
B, Hou J, Shelby H, Graham DY, Streckfus C and Klein JR: MicroRNA
signatures differentiate Crohn's disease from ulcerative colitis.
BMC Immunol. 16:52015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hoss AG, Labadorf A, Latourelle JC, Kartha
VK, Hadzi TC, Gusella JF, MacDonald ME, Chen JF, Akbarian S, Weng
Z, et al: miR-10b-5p expression in Huntington's disease brain
relates to age of onset and the extent of striatal involvement. BMC
Med Genomics. 8:102015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Trionfini P, Benigni A and Remuzzi G:
MicroRNAs in kidney physiology and disease. Nat Rev Nephrol.
11:23–33. 2015. View Article : Google Scholar
|
12
|
Gupta S and Li L: Modulation of miRNAs in
pulmonary hypertension. Int J Hypertens. 2015:1690692015.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kong W, He L, Richards EJ, Challa S, Xu
CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, et
al: Upregulation of miRNA-155 promotes tumour angiogenesis by
targeting VHL and is associated with poor prognosis and
triple-negative breast cancer. Oncogene. 33:679–689. 2014.
View Article : Google Scholar :
|
15
|
Yang YK, Xi WY, Xi RX, Li JY, Li Q and Gao
YE: MicroRNA-494 promotes cervical cancer proliferation through the
regulation of PTEN. Oncol Rep. 33:2393–2401. 2015.PubMed/NCBI
|
16
|
Zhang Y, Han T, Wei G and Wang Y:
Inhibition of microRNA-17/20a suppresses cell proliferation in
gastric cancer by modulating UBE2C expression. Oncol Rep.
33:2529–2536. 2015.PubMed/NCBI
|
17
|
Cao Q, Dong P and Wang Y, Zhang J, Shi X
and Wang Y: miR-218 suppresses cardiac myxoma proliferation by
targeting myocyte enhancer factor 2D. Oncol Rep. 33:2606–2612.
2015.PubMed/NCBI
|
18
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
96(Suppl): R40–R44. 2007.PubMed/NCBI
|
19
|
Wang Z, Ma X, Cai Q, Wang X, Yu B, Cai Q,
Liu B, Zhu Z and Li C: MiR-199a-3p promotes gastric cancer
progression by targeting ZHX1. FEBS Lett. 588:4504–4512. 2014.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Yao YS, Qiu WS, Yao RY, Zhang Q, Zhuang
LK, Zhou F, Sun LB and Yue L: miR-141 confers docetaxel
chemoresistance of breast cancer cells via regulation of EIF4E
expression. Oncol Rep. 33:2504–2512. 2015.PubMed/NCBI
|
21
|
Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F, Yao
H, Song E, Chen Y, Wang M, et al: The overexpression of
hypomethylated miR-663 induces chemotherapy resistance in human
breast cancer cells by targeting heparin sulfate proteoglycan 2
(HSPG2). J Biol Chem. 288:10973–10985. 2013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Feng B, Wang R, Song HZ and Chen LB:
MicroRNA-200b reverses chemoresistance of docetaxel-resistant human
lung adenocarcinoma cells by targeting E2F3. Cancer. 118:3365–3376.
2012. View Article : Google Scholar
|
23
|
Lee D, Sun S, Zhang XQ, Zhang PD, Ho AS,
Kiang KM, Fung CF, Lui WM and Leung GK: MicroRNA-210 and
endoplasmic reticulum chaperones in the regulation of
chemoresistance in glioblastoma. J Cancer. 6:227–232. 2015.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhou Y, Wang M, Wu J, Jie Z, Chang S and
Shuang T: The clinicopathological significance of miR-1307 in
chemotherapy resistant epithelial ovarian cancer. J Ovarian Res.
8:232015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Li M, He XY, Zhang ZM, Li S, Ren LH, Cao
RS, Feng YD, Ji YL, Zhao Y and Shi RH: MicroRNA-1290 promotes
esophageal squamous cell carcinoma cell proliferation and
metastasis. World J Gastroenterol. 21:3245–3255. 2015.PubMed/NCBI
|
26
|
Wang Y, Zang W, Du Y, Ma Y, Li M, Li P,
Chen X, Wang T, Dong Z and Zhao G: Mir-655 upregulation suppresses
cell invasion by targeting pituitary tumor-transforming gene-1 in
esophageal squamous cell carcinoma. J Transl Med. 11:3012013.
View Article : Google Scholar
|
27
|
Isozaki Y, Hoshino I, Akutsu Y, Hanari N,
Mori M, Nishimori T, Murakami K, Akanuma N, Takeshita N, Maruyama
T, et al: Usefulness of microRNA 375 as a prognostic and
therapeutic tool in esophageal squamous cell carcinoma. Int J
Oncol. 46:1059–1066. 2015.
|
28
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human microRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
29
|
Song ZB, Gao SS, Yi XN, Li YJ, Wang QM,
Zhuang ZH and Wang LD: Expression of MUC1 in esophageal
squamous-cell carcinoma and its relationship with prognosis of
patients from Linzhou city, a high incidence area of northern
China. World J Gastroenterol. 9:404–407. 2003.PubMed/NCBI
|
30
|
Li W, Jiang G, Zhou J, Wang H, Gong Z,
Zhang Z, Min K, Zhu H and Tan Y: Downregulation of miR-140 induces
EMT and promotes invasion by targeting Slug in esophageal cancer.
Cell Physiol Biochem. 34:1466–1476. 2014. View Article : Google Scholar
|
31
|
Wang Z, Qiao Q, Chen M, Li X, Wang Z, Liu
C and Xie Z: miR-625 down-regulation promotes proliferation and
invasion in esophageal cancer by targeting Sox2. FEBS Lett.
588:915–921. 2014. View Article : Google Scholar : PubMed/NCBI
|
32
|
Guo Y, Chen Z, Zhang L, Zhou F, Shi S,
Feng X, Li B, Meng X, Ma X, Luo M, et al: Distinctive microRNA
profiles relating to patient survival in esophageal squamous cell
carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
33
|
Kufe DW: Functional targeting of the MUC1
oncogene in human cancers. Cancer Biol Ther. 8:1197–1203. 2009.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
35
|
Banerjee D, Fernandez HR, Patil PB,
Premaratne P, Quiding-Järbrink M and Lindén SK: Epithelial MUC1
promotes cell migration, reduces apoptosis and affects levels of
mucosal modulators during acetylsalicylic acid (aspirin)-induced
gastropathy. Biochem J. 465:423–431. 2015. View Article : Google Scholar
|
36
|
Singh PK and Hollingsworth MA: Cell
surface-associated mucins in signal transduction. Trends Cell Biol.
16:467–476. 2006. View Article : Google Scholar : PubMed/NCBI
|
37
|
Mather IH, Jack LJ, Madara PJ and Johnson
VG: The distribution of MUC1, an apical membrane glycoprotein, in
mammary epithelial cells at the resolution of the electron
microscope: Implications for the mechanism of milk secretion. Cell
Tissue Res. 304:91–101. 2001. View Article : Google Scholar : PubMed/NCBI
|
38
|
Nath S and Mukherjee P: MUC1: A
multifaceted oncoprotein with a key role in cancer progression.
Trends Mol Med. 20:332–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Raina D, Ahmad R, Chen D, Kumar S,
Kharbanda S and Kufe D: MUC1 oncoprotein suppresses activation of
the ARF-MDM2-p53 pathway. Cancer Biol Ther. 7:1959–1967. 2008.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Mori Y, Akita K, Tanida S, Ishida A, Toda
M, Inoue M, Yashiro M, Sawada T, Hirakawa K and Nakada H: MUC1
protein induces urokinase-type plasminogen activator (uPA) by
forming a complex with NF-κB p65 transcription factor and binding
to the uPA promoter, leading to enhanced invasiveness of cancer
cells. J Biol Chem. 289:35193–35204. 2014. View Article : Google Scholar : PubMed/NCBI
|
41
|
Gronnier C, Bruyère E, Lahdaoui F,
Jonckheere N, Perrais M, Leteurtre E, Piessen G, Mariette C and Van
Seuningen I: The MUC1 mucin regulates the tumorigenic properties of
human esophageal adenocarcinomatous cells. Biochim Biophys Acta.
1843:2432–2437. 2014. View Article : Google Scholar : PubMed/NCBI
|